Name in SEC filings: Revolution Medicines, Inc.
| Program | Event | Stage | Stated timing | Filing |
|---|---|---|---|---|
| RAS(ON) inhibitor combinations | /data readout | Stage not stated | fourth quarter of 2026 | 10-Q · |
| RMC-5127 | Topline/data readout | Stage not stated | 2027 | 10-Q · |
| daraxonrasib | Topline/data readout | Phase 3 | 2027 | 8-K · |
Source: ORION, orionbiotechai.com/company/RVMD, data as of Oct 13, 2026
https://www.orionbiotechai.com/company/RVMD
RAS(ON) inhibitor combinations · Topline/data readout · fourth quarter of 2026
SEC sources last checked .
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
Topline/data readoutfourth quarter of 2026
Stage: Not stated
Public float: $6,700,000,000 · as of · SEC filing
We currently expect to provide updated combination data in CRC in the fourth quarter of 2026.
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readout2027
Stage: Not stated
Public float: $6,700,000,000 · as of · SEC filing
share initial clinical data in 2027.
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-12)
Topline/data readout2027
Stage: Phase 3SEC filing · “Phase 3”
Public float: $6,700,000,000 · as of · SEC filing
Enrollment in the global Phase 3 RASolve 301 trial evaluating daraxonrasib in patients with previously treated RAS mutant NSCLC is expected to be completed this year, supporting an anticipated initial readout in 2027.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-12)
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
| Program / event | Stated period and SEC wording | Disclosure in stated period |
|---|---|---|
| daraxonrasibClinical results | 2027“Enrollment in the global Phase 3 RASolve 301 trial evaluating daraxonrasib in patients with previously treated RAS mutant NSCLC is expected to be completed this year, supporting an anticipated initial readout in 2027.” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| RAS(ON) inhibitor combinationsClinical results | fourth quarter of 2026“We currently expect to provide updated combination data in CRC in the fourth quarter of 2026.” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| RMC-5127Clinical results | 2027“share initial clinical data in 2027.” Filed · 10-Q | Period not started The stated period has not started yet, so there is nothing to compare. |
| RAS(ON) inhibitor combinationsClinical results | 2026“We currently expect to provide updated combination data in CRC in 2026.” Filed · 10-Q | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
RASolve 301: comparing daraxonrasib against docetaxel in patients with locally advanced or metastatic RAS mutant NSCLC who have been treated with immunotherapy and platinum-containing chemotherapy. We currently expect to complete enrollment in RASolve 301 in 2026, to enable an expected clinical readout in 2027; and
Historical summaries and source dates are retained separately from the SEC timing quotes above. Earlier publications were collected retrospectively.
Historical catalog checked .
No historical announcement trail is retained for this company in this catalog.
Original ClinicalTrials.gov record · Open the selected study
These are selected linked records and dated source metadata, not a live registry recheck or the company’s full pipeline. Company announcements and the selected registry study are separate evidence sets. No stage or event timing is borrowed between them.
Coverage and identity checksSuggest an SEC timing statement to add for RVMD. You can include the original filing link in your note. The founder reads each request by hand.
Or email ORION.
See RVMD in the calendar · Review labels and methodology